Diagnostic Specialty Antibodies Market (Antibody Type - Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies; Application - Hepatitis Diagnosis, Tuberculosis Diagnostics, Dengue Diagnostics, Oncology Diagnostics, HIV Diagnostics, Infectious Disease Diagnostics; End user - Hospitals, Diagnostic Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

Description

The global diagnostic specialty antibody market for the historical period 2017–2018 and forecast period 2019–2027, advancements in antibody development technology have revolutionized the diagnostic science through which antibodies can be produced against any pathogenic antigen and transformed the diagnostic industry.

According to the report, the global diagnostic specialty antibody market was valued at US$ 22.6 Bn in 2018 and is anticipated to expand at a CAGR of 5.3% from 2019 to 2027

Increase in Reported Cases of Diagnostic Specialty Antibody: A Key Driver

Increase in clinical research, evolution of infectious diseases, and unhealthy lifestyle of the population has led to innovation of new biological drugs as well as diagnostic kits. Several biotechnology and biopharmaceutical companies offer different diagnostic assays to meet the unmet medical needs of the health care system, which augment the diagnostic specialty antibody market.

In 2014, Epitope Diagnostics, Inc. launched a new set of monoclonal antibody MMAE-ADC and MMAF-ADC ELISA kits, which are specific to detecting monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF), the two anti-cancer compounds. Launch of such innovative antibody based diagnostic kits is likely to enable the measurement of the disease condition more accurately. This is likely to increase interest of diagnostic laboratories and hospitals to use these products, which are likely ti augment the growth of diagnostic specialty antibody market

Governments of several countries are investing in diagnostic health care. According to the World Bank, global healthcare expenditure was 6% of GDP. In 2016, world health care expenditure was US$ 6.5 Trn. In 2015, health care spending in the U.S. increased by 5.8% to reach US$ 3.2 Trn. The overall share of the U.S. economy devoted to health care spending was 17.8% in 2015, up from 17.4% in 2014. In 2015, total government health care expenditure in Europe was 7.2% of GDP.

With respect to government investment in developing antibody-based diagnostic kits, in February 2018, the Bio & Medical Technology Development Program of the National Research Foundation of Korea developed a rapid diagnostic test kit to detect IgG and IgM antibody against Zika virus using monoclonal antibodies and the whole research was funded by the Government of South Korea, likely to drive the diagnostic specialty antibody market.

Get a glimpse of the in-depth analysis through our Report Brochure

Failure of Antibodies in Rapid Diagnostic Test for Routine Diagnosis to Hamper Global Diagnostic Specialty Antibody Market

The Ministry of Health and Family Welfare, Government of India, indicated that the use of antibody detecting rapid diagnostic test (ADRDTs) is not the solution to diagnosis of diseases such as malaria, because serelogical testing is not practical for routine diagnosis of an acute parasite infectious disease in terms of the time required for development of antibody. Moreover, in endemic areas of India, the antibody detecting rapid diagnostic test gave false positive test results, as patients suffer due to other reasons. Hence, from March 2018, the Ministry of Health and Family Welfare, prohibited the use of antibody detecting rapid diagnostic tests for routine diagnosis of malaria. Such incidences are projected to hamper the growth of the diagnostic specialty antibody market.

North America to Account for Major Share of Global Diagnostic specialty antibody Market

North America leads the global diagnostic specialty antibody market commanding more than 40% share in the global diagnostic specialty antibody market. Recent advances in diagnostic specialty antibody diagnostics, reimbursement for disease screening, and improved access to diagnostics are the major drivers of the diagnostic specialty antibody market in North America.  U.S. is expected to hold major share in the North America diagnostic specialty antibody market during the forecast period, owing to developed health care infrastructure in the region and large patient population along with increasing technological development.

Increase in government intervention in the emerging markets has led to rise in awareness about diseases and improvement in the health care infrastructure. Additionally, socioeconomic development has been observed in emerging economies such as Asia, Africa, and Latin America. These factors contribute to the overall increase in spending capacity of the population which likely expect to increase market share of Asia, Africa, and Latin America diagnostic specialty antibody market.

Moreover, prevalence of life threatening diseases and infectious diseases such as COVID-19 is high in these regions. According to the WHO estimates, 4.2 million cases were detected till May 13 2020, with nearly 2.9 lakh COVID-19 related deaths. The number of COVID cases is expected to increase across the globe, with 50% of cases in Africa, Asia, and Latin America. Hence, increase in investment in these emerging markets is a major opportunity for key players, and these are anticipated to be major markets for diagnostic specialty antibody infection.

Global Diagnostic Specialty Antibody Market: Competitive Landscape

This report profiles major players in the global diagnostic specialty antibody market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

Key players operating in the global diagnostic specialty antibody market include Abcam plc, Sanofi, Abbott laboratories, Hoffmann-La Roche Ltd., Danaher Corporation, Bio-Rad Laboratories, Inc., Boehringer Ingelheim International GmbH, Agilent Technologies, Inc., and Aytu BioScience, Inc.

Leading players operating in the global diagnostic specialty antibody market are

  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Abbott Laboratories.
  • These players offer products with proprietary technologies. Others include
  • Abcam plc
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim International GmbH
  • Agilent Technologies, Inc.
  • Aytu BioScience, Inc.
  • Aytu Bioscience, Inc.

invests in research and developmental activities to develop new and innovative products. It recently acquired and anticipates to commercialize FDA-approved ProstaScint (capromab pendetide), a radiolabeled monoclonal antibody. In January 2016, the company acquired a high-performance analytical flow cytometer platform from Propel Labs. This enables advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries.

Key Questions Answered in Global Diagnostic Specialty Antibody Market Report

  • What is the scope of growth of product companies in the global diagnostic specialty antibody market?
  • What will be the Y-o-Y growth of the global diagnostic specialty antibody market between 2019 and 2027?
  • What is the influence of changing trends in antibodies on the global diagnostic specialty antibody market?
  • Will North America continue to be the most profitable market for providers of diagnostic specialty antibody treatment products?
  • Which factors will hamper the growth of the global diagnostic specialty antibody market during the forecast period?
  • Which are the leading companies in the global diagnostic specialty antibody market?

The global diagnostic specialty antibodies market has been segmented as follows:

Antibody Type

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Polyclonal Antibodies

Application

  • Hepatitis Diagnosis
  • Tuberculosis Diagnostics
  • Dengue Diagnostics
  • Oncology Diagnostics
  • HIV Diagnostics
  • Infectious Disease Diagnostics
  • Others

End-user

  • Hospitals
  • Diagnostic Laboratories
  • Others

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Australia & New Zealand
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • South Africa
  • GCC Countries
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Diagnostic Specialty Antibody Market

4. Market Overview

    4.1. Introduction

        4.1.1. Antibody Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Diagnostic Specialty Antibody Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Market Outlook

    5.1. Disease Prevalence & Incidence Rate globally with key countries / Region

    5.2. Pipeline Analysis

    5.3. Key Industry Developments

6. Global Diagnostic Specialty Antibody Market Analysis and Forecast, by Antibody Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Antibody Type, 2017–2027

        6.3.1. Monoclonal Antibodies

        6.3.2. Polyclonal Antibodies

        6.3.3. Recombinant Polyclonal Antibodies

    6.4. Market Attractiveness, by Antibody Type 

7. Global Diagnostic Specialty Antibody Market Analysis and Forecast, by End-user 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by End-user, 2017–2027

        7.3.1. Hospitals

        7.3.2. Diagnostic Laboratories

        7.3.3. Others

    7.4. Market Attractiveness Analysis, by End-user

8. Global Diagnostic Specialty Antibody Market Analysis and Forecast, by Application 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Application, 2017–2027

        8.3.1. Hepatitis Diagnosis

        8.3.2. Tuberculosis Diagnostics

        8.3.3. Dengue Diagnostics

        8.3.4. Oncology Diagnostics

        8.3.5. HIV Diagnostics

        8.3.6. Infectious Disease Diagnostics

        8.3.7. Others Diagnostics

    8.4. Market Attractiveness Analysis, by Application

9. Global Diagnostic Specialty Antibody Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness Analysis, by Region

10. North America Diagnostic Specialty Antibody Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast By Antibody Type, 2017–2027

        10.2.1. Monoclonal Antibodies

        10.2.2. Polyclonal Antibodies

        10.2.3. Recombinant Polyclonal Antibodies

    10.3. Market Value Forecast, by End-user, 2017–2027

        10.3.1. Hospitals

        10.3.2. Diagnostic Laboratories

        10.3.3. Others

    10.4. Market Value Forecast, by Application, 2017–2027

        10.4.1. Hepatitis Diagnosis

        10.4.2. Tuberculosis Diagnostics

        10.4.3. Dengue Diagnostics

        10.4.4. Oncology Diagnostics

        10.4.5. HIV Diagnostics

        10.4.6. Infectious Disease Diagnostics

        10.4.7. Others Diagnostics

    10.5. Market Value Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Antibody Type 

        10.6.2. By End-user 

        10.6.3. By Application

        10.6.4. By Country

11. Europe Diagnostic Specialty Antibody Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Antibody Type, 2017–2027

        11.2.1. Monoclonal Antibodies

        11.2.2. Polyclonal Antibodies

        11.2.3. Recombinant Polyclonal Antibodies

    11.3. Market Value Forecast, by End-user, 2017–2027

        11.3.1. Hospitals

        11.3.2. Diagnostic Laboratories

        11.3.3. Others

    11.4. Market Value Forecast, by Application, 2017–2027

        11.4.1. Hepatitis Diagnosis

        11.4.2. Tuberculosis Diagnostics

        11.4.3. Dengue Diagnostics

        11.4.4. Oncology Diagnostics

        11.4.5. HIV Diagnostics

        11.4.6. Infectious Disease Diagnostics

        11.4.7. Others Diagnostics

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Antibody Type 

        11.6.2. By End-user 

        11.6.3. By Application

        11.6.4. By Country/Sub-region

12. Asia Pacific Diagnostic Specialty Antibody Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Antibody Type, 2017–2027

        12.2.1. Monoclonal Antibodies

        12.2.2. Polyclonal Antibodies

        12.2.3. Recombinant Polyclonal Antibodies

    12.3. Market Value Forecast, by End-user, 2017–2027

        12.3.1. Hospitals

        12.3.2. Diagnostic Laboratories

        12.3.3. Others

    12.4. Market Value Forecast, by Application, 2017–2027

        12.4.1. Hepatitis Diagnosis

        12.4.2. Tuberculosis Diagnostics

        12.4.3. Dengue Diagnostics

        12.4.4. Oncology Diagnostics

        12.4.5. HIV Diagnostics

        12.4.6. Infectious Disease Diagnostics

        12.4.7. Others Diagnostics

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis 

        12.6.1. By Antibody Type 

        12.6.2. By End-user 

        12.6.3. By Application

        12.6.4. By Country/Sub-region

13. Latin America Diagnostic Specialty Antibody Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Antibody Type, 2017–2027

        13.2.1. Monoclonal Antibodies

        13.2.2. Polyclonal Antibodies

        13.2.3. Recombinant Polyclonal Antibodies

    13.3. Market Value Forecast, by End-user, 2017–2027

        13.3.1. Hospitals

        13.3.2. Diagnostic Laboratories

        13.3.3. Others

    13.4. Market Value Forecast, by Application, 2017–2027

        13.4.1. Hepatitis Diagnosis

        13.4.2. Tuberculosis Diagnostics

        13.4.3. Dengue Diagnostics

        13.4.4. Oncology Diagnostics

        13.4.5. HIV Diagnostics

        13.4.6. Infectious Disease Diagnostics

        13.4.7. Others Diagnostics

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis 

        13.6.1. By Antibody Type 

        13.6.2. By End-user 

        13.6.3. By Application

        13.6.4. By Country/Sub-region

14. Middle East & Africa Diagnostic Specialty Antibody Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Antibody Type, 2017–2027

        14.2.1. Monoclonal Antibodies

        14.2.2. Polyclonal Antibodies

        14.2.3. Recombinant Polyclonal Antibodies

    14.3. Market Value Forecast, by End-user, 2017–2027

        14.3.1. Hospitals

        14.3.2. Diagnostic Laboratories

        14.3.3. Others

    14.4. Market Value Forecast, by Application, 2017–2027

        14.4.1. Hepatitis Diagnosis

        14.4.2. Tuberculosis Diagnostics

        14.4.3. Dengue Diagnostics

        14.4.4. Oncology Diagnostics

        14.4.5. HIV Diagnostics

        14.4.6. Infectious Disease Diagnostics

        14.4.7. Others Diagnostics

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis 

        14.6.1. By Antibody Type 

        14.6.2. By End-user 

        14.6.3. By Application

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (By Tier and Size of companies)

    15.2. Market Share/Position Analysis, by Company, 2018

    15.3. Company Profiles

        15.3.1. Abcam plc

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Growth Strategies

            15.3.1.3. SWOT Analysis

        15.3.2. F. Hoffmann-La Roche Ltd. 

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Growth Strategies

            15.3.2.3. SWOT Analysis

        15.3.3. Abbott Laboratories

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Growth Strategies

            15.3.3.3. SWOT Analysis

        15.3.4. Sanofi

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Growth Strategies

            15.3.4.3. SWOT Analysis

        15.3.5. Bio-Rad Laboratories, Inc.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Growth Strategies

            15.3.5.3. SWOT Analysis

        15.3.6. Boehringer Ingelheim International GmbH

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Growth Strategies

            15.3.6.3. SWOT Analysis

        15.3.7. Agilent Technologies, Inc. 

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Growth Strategies

            15.3.7.3. SWOT Analysis

        15.3.8. Aytu BioScience, Inc.  

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Growth Strategies

            15.3.8.3. SWOT Analysis

Choose License Type

Checkout Inquiry Sample